Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any nephrotic syndrome in which the cause of the disease is a mutation in the EMP2 gene.
Features include always present findings: Nephrotic syndrome and Minimal change glomerulonephritis; and sometimes findings: Steroid-resistant nephrotic syndrome. 4 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 3 | Nephrotic syndrome, Steroid-resistant nephrotic syndrome, Minimal change glomerulonephritis |
EMP2 encodes epithelial membrane protein 2 (167 aa). Functions as a key regulator of cell membrane composition by regulating protein surface expression. Highest expression in Lung (271.7 TPM) and Skin Not Sun Exposed Suprapubic (123.1 TPM).
Nephrotic syndrome, type 10 is associated with mutations in the EMP2 gene on chromosome 16.
EMP2 is classified as a druggable target (Cell Surface category) with score 8.7.
Genetic testing for EMP2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for nephrotic syndrome, type 10 has been reported in the published literature.
Phenotype severity distribution: 2 always present features.
No clinical trials have been registered for nephrotic syndrome, type 10.
60 publications have been identified in PubMed for nephrotic syndrome, type 10. Research spans Case Report / Case Series (30%), Epidemiology / Natural History (25%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 18 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:12 PM UTC
Online Mendelian Inheritance in Man
Arms and legs |
1 |
Podocyte foot process effacement |
Age of onset: childhood.
Disease patterns and progression
15 |
25% |
Laboratory research | 9 | 15% |
Research summaries | 8 | 13% |
New treatment approaches | 4 | 7% |
Clinical study results | 3 | 5% |
Testing and diagnosis research | 2 | 3% |
Other research | 1 | 2% |
Henriques AR (2026). [PMID: 41852509](https://pubmed.ncbi.nlm.nih.gov/41852509/). *Front Nephrol*. [Case Report / Case Series]
Xue D (2026). [PMID: 42221131](https://pubmed.ncbi.nlm.nih.gov/42221131/). *Front Med (Lausanne)*. [Case Report / Case Series]
Ghai R (2026). [PMID: 42083774](https://pubmed.ncbi.nlm.nih.gov/42083774/). *Ann Afr Med*. [Epidemiology / Natural History]
Angioi A (2026). [PMID: 41898697](https://pubmed.ncbi.nlm.nih.gov/41898697/). *Int J Mol Sci*. [Case Report / Case Series]
Xiang S (2026). [PMID: 42232968](https://pubmed.ncbi.nlm.nih.gov/42232968/). *Front Med (Lausanne)*. [Case Report / Case Series]
Bhaumik A (2026). [PMID: 42078290](https://pubmed.ncbi.nlm.nih.gov/42078290/). *Cureus*. [Epidemiology / Natural History]
Yoshida R (2026). [PMID: 42016443](https://pubmed.ncbi.nlm.nih.gov/42016443/). *Kidney Med*. [Epidemiology / Natural History]
Dong R (2026). [PMID: 42116397](https://pubmed.ncbi.nlm.nih.gov/42116397/). *Medicine (Baltimore)*. [Epidemiology / Natural History]
Sahu S (2026). [PMID: 39589174](https://pubmed.ncbi.nlm.nih.gov/39589174/). *J Biomol Struct Dyn*. [Basic Science / Preclinical]
Kondoh T (2026). [PMID: 41563417](https://pubmed.ncbi.nlm.nih.gov/41563417/). *Pediatr Nephrol*. [Basic Science / Preclinical]